Stocktoria
MeiraGTx Holdings plc MGTX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-06-08
Chart by TradingView
3/9
Piotroski F — financial health
-14.65
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $81.4M | $33.3M | $14.0M | $15.9M | $37.7M |
| Operating income | -$106.0M | -$164.2M | -$137.1M | -$116.4M | -$72.8M |
| Net income | -$114.2M | -$147.8M | -$84.0M | -$129.6M | -$79.6M |
| Operating cash flow | -$46.4M | -$104.5M | -$105.4M | -$73.1M | -$10.5M |
| Free cash flow | -$50.2M | -$109.5M | -$125.5M | -$118.1M | -$56.9M |
| Total assets | $244.4M | $269.8M | $326.7M | $318.2M | $320.2M |
| Total liabilities | $250.2M | $201.9M | $188.6M | $200.5M | $134.8M |
| Shareholders' equity | -$5.8M | $67.8M | $138.2M | $117.7M | $185.4M |
| Ratios | |||||
| Operating margin | -130.2% | -493.4% | -977.8% | -730.9% | -193.0% |
| Net margin | -140.3% | -444.1% | -599.5% | -814.2% | -211.0% |
| FCF margin | -61.7% | -328.9% | -895.6% | -741.6% | -150.9% |
| Return on assets | -46.7% | -54.8% | -25.7% | -40.7% | -24.9% |
| Return on equity | 1971.4% | -217.9% | -60.8% | -110.1% | -42.9% |
| Current ratio | 0.75 | 2.03 | 2.38 | 1.88 | 2.69 |
| Revenue growth | 144.6% | 137.4% | -12.0% | -57.8% | 142.2% |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -14.65 (distress)
- Working capital / assets -0.126
- Retained earnings / assets -3.339
- EBIT / assets -0.434
- Equity / liabilities -0.023
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001735438 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.